
Subject:

FW: Aqvesme, Pyrukynd (Mitapivat Sulfate Tablets) - Petition for Inter Partes Review

From: Omar Jabri <ojabri@apotex.com>**Sent:** Wednesday, April 8, 2026 9:30 AM**To:** Jim Burns <Jim.Burns@agios.com>**Subject:** Aqvesme, Pyrukynd (Mitapivat Sulfate Tablets) - Petition for Inter Partes Review

[EXTERNAL EMAIL]

Mr. Burns:

I serve as Head of IP Strategy for Apotex Inc., a generic pharmaceutical company headquartered in Toronto. Apotex's core mission is to improve everyday access to affordable, innovative medicines and health products for patients and consumers worldwide.

I am reaching out in your capacity as Chief Legal Officer of Agios Pharmaceuticals Inc. to explore an opportunity for pre-dispute discussions regarding U.S. Patent No. 11,878,049 (the "'049 patent"), which is listed in the FDA's Orange Book for Aqvesme® and Pyrukynd® (mitapivat sulfate tablets). Our aim is to explore a mutually advantageous business resolution.

We believe a direct, business-to-business dialogue is the most efficient way to avoid the substantial cost and risk associated with inter partes review of the '049 patent. To that end, Apotex would welcome a brief introductory call to share additional context and explore options. By way of example, and without limitation, Apotex would be open to discussing the terms of a license under the '049 patent to further our goal of bringing affordable generic options to patients. To the extent it would be helpful to Agios to evaluate this opportunity, Apotex is willing to share a copy of the IPR petition and expert declaration under suitable confidentiality protections.

If convenient, please let me know a few windows in the coming days for a short call, or I can propose times that work on my end.

Thank you for your consideration. I look forward to your response.

Best regards,

Omar

[Omar Jabri](#)

Head of IP Strategy

Apotex Inc.

Cell: 416-574-7616 | www.apotex.com [in](#)

APOTEX